BMS beats analysts' Q2 projections
Despite competition coming in from generics, sales of cancer treatment Revlimid have fared better than anticipated in Bristol Myers Squibb’s second quarter.
by marketwire, translated by daniel pedersen
US-based pharmaceutical giant Bristol Myers Squibb has outperformed sales expectations in the second quarter of the year, partially driven by sales of Revlimid, a cancer drug, dropping less than what was guided for due to competition from generics.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Boston Scientific exceeds most expectations in Q2
For subscribers
